Skip to main content

Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.

Publication ,  Journal Article
Gadde, KM; Yonish, GM; Wagner, HR; Foust, MS; Allison, DB
Published in: Int J Obes (Lond)
July 2006

BACKGROUND AND OBJECTIVE: Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults. DESIGN: At 12-week randomised, double-blind, placebo-controlled trial, conducted at Duke University Medical Centre, USA, from May 2004 to December 2004. PARTICIPANTS: A total of 30 obese women (mean (s.e.) body mass index of 36.1 (0.6) kg/m2). INTERVENTIONS: Participants were randomly assigned to receive atomoxetine (n=15) or placebo (n=15). All participants were advised to follow a balanced hypocaloric diet (500 kcal/day deficit). Atomoxetine therapy was started at 25 mg/day orally, with gradual increase to 100 mg/day over 1 week. Placebo dosing was identical. MEASUREMENTS: Body weight in kilograms was the primary outcome measure. Other measurements included waist circumference, blood pressure and heart rate, fasting plasma glucose and lipids, and depressive symptoms. RESULTS: Last-observation-carried-forward analysis of the available data for participants who had completed at least one post-randomisation assessment, demonstrated that the atomoxetine group (n=12) lost more body weight over the 12-week period than the placebo (n=14) group (mean (s.e.) -3.6 (1.0) kg (-3.7% loss) vs 0.1 (0.4) kg (0.2% gain); F (4,96)=11.9; P<0.0001). Three participants in the atomoxetine group and none in the placebo group lost >or=5% weight. Side effects were minimal. CONCLUSION: Atomoxetine demonstrated modest short-term weight loss efficacy relative to placebo in this preliminary study of obese women.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Obes (Lond)

DOI

ISSN

0307-0565

Publication Date

July 2006

Volume

30

Issue

7

Start / End Page

1138 / 1142

Location

England

Related Subject Headings

  • Weight Loss
  • Treatment Outcome
  • Propylamines
  • Obesity
  • Middle Aged
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Double-Blind Method
  • Body Mass Index
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gadde, K. M., Yonish, G. M., Wagner, H. R., Foust, M. S., & Allison, D. B. (2006). Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond), 30(7), 1138–1142. https://doi.org/10.1038/sj.ijo.0803223
Gadde, K. M., G. M. Yonish, H. R. Wagner, M. S. Foust, and D. B. Allison. “Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.Int J Obes (Lond) 30, no. 7 (July 2006): 1138–42. https://doi.org/10.1038/sj.ijo.0803223.
Gadde KM, Yonish GM, Wagner HR, Foust MS, Allison DB. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond). 2006 Jul;30(7):1138–42.
Gadde, K. M., et al. “Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.Int J Obes (Lond), vol. 30, no. 7, July 2006, pp. 1138–42. Pubmed, doi:10.1038/sj.ijo.0803223.
Gadde KM, Yonish GM, Wagner HR, Foust MS, Allison DB. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond). 2006 Jul;30(7):1138–1142.

Published In

Int J Obes (Lond)

DOI

ISSN

0307-0565

Publication Date

July 2006

Volume

30

Issue

7

Start / End Page

1138 / 1142

Location

England

Related Subject Headings

  • Weight Loss
  • Treatment Outcome
  • Propylamines
  • Obesity
  • Middle Aged
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Double-Blind Method
  • Body Mass Index